Seeking Alpha reports that RXi Pharmaceuticals Corporation shares closed up more than 10% on Thursday based upon "credible rumors" that the company was a possible acquisition target by one of the major big pharma players. RXi is one of the leaders in RNAi based drug discovery and development.
On September 8th, I reported a similar story concerning Silence Therapeutics being approached by another large pharma player"that may or may not lead to an offer." Silence has deals with current big pharma in AstraZeneca and Novartis.
RNAi technology can be expected to be another popular area for big pharma to enter to spur new drug development and discovery - so that the concept that big pharma companies would be circling RNAi companies to me is creidble. This is especially so - given some of the problems internal develoment groups have had in big pharma coupled with their well documented revenue interruptions looming due to the "patent cliff".
Posted by Bruce Lehr September 12th 2010.